2004


To access this material please log in or register

Register Authorize
2004/№3

I1-Imidazoline agonists in the treatment of cardiovascular diseases

Kobalava Zh.D., Lobankova L.A., Lobzhanidze T.V., Kotovskaya Yu.V.

Keywords:

DOI:

I1-Imidazoline agonists are centrally active drugs of new generation, which have been used since the early 1980s. The
principal drugs of this class currently used in clinical practice are moxonidine and rilmendine. Studies performed with these drugs have supported their good antihypertensive efficacy and tolerability both as monotherapy and in combination with other classes of antihypertensive drugs; ability for improving parameters of carbohydrate metabolism in patients with the metabolic syndrome; reduction of left ventricular hypertrophy (LVH); improvement of renal functional state in patients with diabetic nephropathy; and improvement of microvasculature condition. Results of the study MOXON have substantiated the attribution of severe heart failure to relative contraindications for this drug class. Results of large-scale multicenter studies on the effect of this drug class on survival and risk for cardiovascular complications in patients with arterial hypertension (AH) are limited at the present time.

To access this material please log in or register

Register Authorize
Ru En